uQuantEV · Microfluidic EV Quantification for Point-of-Care CRC diagnostics
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2024-09-01 → 2027-03-31
- Финансиране от ЕС
- 165 313 €
- Участници
- 2
- Схема
- HORIZON-TMA-MSCA-PF-EF
Линиите свързват координатора с партньорите.
Накратко на български
Микрофлуидни чипове се разработват за бързо откриване на специфични везикули (малки частици), които ракът на дебелото черво отделя в организма. Това позволява по-евтина, неинвазивна и ранна диагностика на заболяването, която може да се извърши директно в лечебното заведение.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
The μQuantEV project aims to revolutionize the landscape of colorectal cancer (CRC) diagnostics through the development of a groundbreaking Point-of-Care (PoC) platform. Leveraging the emerging potential of extracellular vesicles (EVs) as robust biomarkers for CRC, this interdisciplinary endeavor combines cutting-edge microfluidic technology with advanced analytical methods to enable the sensitive, rapid, and cost-effective detection of CRC-specific EVs.By designing, fabricating, and characterizing a microfluidic EV enrichment module, the project pioneers an innovative approach for the selective capture of CRC-associated EVs from patient-derived samples. Simultaneously, a state-of-the-art fluorescence-based EV detection and quantification module is developed to provide accurate and real-time analysis of the captured EVs. These two modules are seamlessly integrated to create a Lab-on-a-Chip diagnostic platform capable of detecting CRC at early stages with exceptional sensitivity and specificity.Furthermore, μQuantEV places a strong emphasis on translational research, collaborating closely with clinical partners to validate the platform's performance using patient samples. The project also incorporates extensive open science practices to foster collaboration, transparency, dissemination of research outcomes.Upon successful completion, the μQuantEV platform holds the potential to revolutionize CRC diagnostics, offering a cost-effective, non-invasive, and efficient alternative to current screening methods. Beyond CRC, the technology developed in this project can pave the way for the application of EV-based diagnostics in various other diseases, driving advancements in personalized medicine and improving healthcare outcomes.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSIDAD DE OVIEDO · OVIEDOКоординаторИспания
- INTERNATIONAL IBERIAN NANOTECHNOLOGY LABORATORY · BragaПортугалия
Връзки
- Виж в CORDIS
- DOI: 10.3030/101153594
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5202d38a2&appId=PPGMS
Данни: CORDIS, © Европейски съюз